N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=162 Lurasidone Extended Use Study
Schizophrenia · Bipolar Disorder
Primary: Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs — 63; 7; 10 participants
Phase 3 N=403 Study of Meloxicam Capsules to Treat Osteoarthritis Pain
Osteoarthritis
Primary: Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain…
Phase 4 N=87 Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes
Diabetes Mellitus
Primary: Time in Range — 10.9; 11.5; 13.3; 12.3 hours per day — p=0.9345
N/A N=97 WaveLight® Refractive Myopic Study
Refractive Error
Primary: Least Squares Mean Difference in Binocular UCVA at 1 Month Post-Treatment and Pre-Treatment Binocular BCVA — -0.0519 logMAR
Phase 3 N=191 Pregabalin in Treating Women With Hot Flashes
Breast Cancer · Hot Flashes
Primary: Numerical Change From Baseline in Hot Flash Score at Treatment Week 6 (Positive Numbers to Represent Increases and Negative Numbers to Represent Decreases). — -9.6; -6.1…
Phase 3 N=5,712 A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study — 1.55; 2.52 percentage of participants
Phase 2 N=59 A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants Experiencing a Treatment Emergent Adverse Event — 3; 9; 10 participants
Phase 2 N=58 VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Fallopian Tube Cancer · Malignant Tumor of Peritoneum · Recurrent Ovarian Epithelial Cancer
Primary: Maximum Tolerated Dose of VEGF Trap (Phase I) — 6 mg/kg
Phase 2 N=37 Phase II Study of Vandetanib in Individuals With Kidney Cancer
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
N/A N=51 TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides
Wrinkles · Rhytides
Primary: Changes to the Surface by Visual and Photographic Analysis. — 41 participants
Phase 3 N=432 NVA237 BID Versus Placebo Twelve-week Efficacy Study
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing — 0.115; -0.008 Liters
N/A N=22 Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults
Cognitive Decline · Dementia · Alzheimer's Disease
Primary: Stroop Test Performance From Pre- to Post-intervention — 137.67; 56.17; 116.51; 55.13 Time to complete (seconds)
Phase 4 N=94 Effectiveness and Safety of the Levitan Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway
Airway Complication of Anaesthesia
Primary: Cormack-Lehane Grade — 58; 53; 33; 41 participants